Table 1 Patients’ clinical characteristics, treatment data and outcome measures.

Pts	Age at last follow up (years)	Sex	Disease duration at last follow up	First line treatment (FLT)	FLT duration	IVIG duration	Dose SCIg (gr/week)	SCIg duration	ONLS		MRC s.s.		LQI
Pts	Age at last follow up (years)	Sex	Disease duration at last follow up	First line treatment (FLT)	FLT duration	IVIG duration	Dose SCIg (gr/week)	SCIg duration	T0	T1	T0	T1	T0	T1
1	47	M	19 years	prednisone	12 years	1 year	20	6 years	2	2	78	78	66	90
2	77	M	14 years	prednisone	7 years	2 years	16	5 years	5	5	44	46	44	67
3	58	F	6 years	IVIG	4.5 years	4.5 years	30	5 years	5	5	59	62	59	81
4	54	F	12 years	predn/AZT	1 year	4 years	12	6 years (suspended)	4	4	64	64	85	86
5	48	M	12 years	AZT	4 years	4 years	20	7 years	3	2	66	66	75	99
6	79	M	7 years	IVIG	1 year	1 year	20	6 years	6	3	70	80	85	98
7	60	M	8 years	predn/AZT	1 year	0.5 year	18	7 years	2	1	68	80	82	90
8	74	F	7 years	IVIG	0.5 year	0.5 year	16	6 years	3	1	78	80	82	98
9	72	F	6 years	prednisone	1 year	0.5 year	12	5 years	7	6	69	73	62	78
10	60	F	17 years	prednisone	17 years (ongoing)	11 years	9.6	2 years (suspended)	4	6	68	60	62	70
11	68	M	6 years	prednisone	0.5 year	0.5 year	30	3.5 years	5	5	66	66	60	89
12	56	M	12 years	prednisone	12 years (ongoing)	2 years	30	4.5 years	2	2	75	75	63	92
13	27	M	12 years	IVIG	8 years	8 years	12.8	4 years	2	0	71	80	58	96
14	60	M	7 years	prednisone	0.5 year	0.5 year	15	3 years	2	0	78	80	75	100
15	64	F	13 years	predn/AZT	4 years	4 years	20	3 years	4	3	74	74	56	84
16	55	F	12 years	predn/AZT	0.5 year	4.5 years	12.8	7 years	3	3	76	76	78	95
17	47	M	14 years	prednisone	12 years (ongoing)	1 year	20	2 year	3	2	78	78	64	90

Pts: patients; ONLS: overall neuropathy limitation scale; MRC s.s.: medical research council sum score; LQI: life quality index questionnaire; T0: baseline (at SCIg treatment beginning); T1: last follow-up.

Quick links

Search